Skip to main content
Retour
Watch Compare

Clearside Biomedical, Inc.

Qualité des données : 100%
CLSDQ
OTC Manufacturing Chemicals
0,19 €
▼ 0,02 € (-9,99%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-32,24%

Croissance

Revenue Growth (5Y)
-32,24%
En dessous de la moyenne du secteur (1,92%)
Revenue (1Y)-79,77%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-171,49%
Net Margin-780,90%
Op. Margin-689,76%

Sécurité

Debt / Equity
N/A
Current Ratio2,98
Interest CoverageN/A

Valorisation

PE (TTM)
-0,06
Au-dessus de la moyenne du secteur (-1,50)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -32,24% annually over 5 years
Negative free cash flow of -21,75 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 47,53%

Price History

Tendances Financières

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · Rev Est: 0,0
Q42024 Q12025 Q22025 Q32025 Q1 '26
Reported -1,50 € -1,65 € -0,06 € -1,14 € —
Estimate -1,55 € -1,60 € -1,52 € -0,60 € —
Surprise +3,23% -3,12% +96,06% -90,00% —

Growth

Rev 5Y: -32,24% · Earnings 1Y: N/A
Revenue Growth (1Y) -79,77% Revenue Growth (3Y) 11,98%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -32,24% Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: -780,90%
Revenue (TTM) 3,33 M Net Income (TTM) -26,00 M
ROE N/A ROA -192,76%
Gross Margin N/A Operating Margin -689,76%
Net Margin -780,90% Free Cash Flow (TTM) -21,75 M
ROIC -171,49% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 2,98
Debt / Equity N/A Current Ratio 2,98
Interest Coverage N/A Asset Turnover 0,25
Working Capital 5,48 M Tangible Book Value -53,95 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,06 · EV/EBITDA: N/A
P/E Ratio -0,06 Forward P/E N/A
P/B Ratio N/A P/S Ratio 0,44
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1478,56%
Market Cap 1,47 M Enterprise Value -5,33 M

Per Share

EPS: -3,71 · FCF/Share: -4,15
EPS (Diluted TTM) -3,71 Revenue / Share 0,64
FCF / Share -4,15 OCF / Share -4,07
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 83,65% · CapEx/Rev: 13,61%
CapEx / Revenue 13,61% FCF Conversion 83,65%
SBC-Adj. FCF -25,07 M Growth Momentum -47,53

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1,66 M 8,23 M 1,33 M 29,58 M 7,89 M
Net Income -34,35 M -32,49 M -32,95 M 376 000,0 -18,21 M
EPS (Diluted) -0,47 -0,53 -0,55 0,01 —
Gross Profit — — — — —
Operating Income -28,88 M -24,84 M -30,28 M -627 000,0 -17,94 M
EBITDA — — — — —
R&D Expenses 18,59 M 20,85 M 19,63 M 18,54 M 15,07 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 25,13 M 34,02 M 51,30 M 42,90 M 19,32 M
Total Liabilities 63,98 M 49,93 M 40,70 M 4,93 M 10,56 M
Shareholders' Equity -38,86 M -15,91 M 10,61 M 37,98 M 8,76 M
Total Debt — — — — 3,82 M
Cash & Equivalents 20,02 M 28,92 M 48,26 M 30,44 M 17,29 M
Current Assets 21,27 M 30,12 M 49,40 M 42,14 M 18,12 M
Current Liabilities 4,79 M 6,81 M 5,78 M 4,64 M 9,94 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -0,1 -1,5
P/B — 1,6
ROE % — -54,5
Net Margin % -780,9 -41,5
Rev Growth 5Y % -32,2 1,9
D/E — 0,3